Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The long-lasting dark shadow of past and present smoking

    Research output: Contribution to journalComment/debateResearchpeer-review

  3. Non-eosinophilic severe exacerbations of COPD: what about antibiotics? - Authors' reply

    Research output: Contribution to journalComment/debateResearchpeer-review

  1. First patient with ILNEB syndrome due to pathogenic variants in ITGA3 surviving to adulthood

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hyperbaric oxygen treatment impacts oxidative stress markers in patients with necrotizing soft-tissue infection

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Kongenitte portosystemiske shunter, diagnose og behandling af en multisystemisk sygdom hos børn

    Research output: Contribution to journalReviewResearchpeer-review

  4. Anti-biofilm Approach in Infective Endocarditis Exposes New Treatment Strategies for Improved Outcome

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

BACKGROUND: Use of maintenance antibiotic therapy with the macrolide azithromycin is increasing in a number of chronic respiratory disorders including primary ciliary dyskinesia (PCD). However, evidence for its efficacy in PCD is lacking. We aimed to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in patients with PCD.

METHODS: The Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia (BESTCILIA) trial was a multicentre, double-blind, parallel group, randomised, placebo-controlled phase 3 trial done at 6 European PCD clinics (tertiary paediatric care centres and university hospitals in Denmark, Germany, Netherlands, Switzerland, and UK). Patients with a confirmed diagnosis of PCD, aged 7-50 years old, and predicted FEV1 greater than 40% were recruited. Participants were randomly assigned (1:1), stratified by age and study site, via a web-based randomisation system to azithromycin 250 mg or 500 mg as tablets according to bodyweight (</≥ 40 kg) or identical placebo, three times a week for 6 months. The random allocation sequence was a permuted block randomisation, with a block size of four, generated by an external consultancy. Participants, investigators, and care providers were masked to treatment allocation. The primary endpoint was the number of respiratory exacerbations over 6 months. Analysis was by intention to treat. This study is registered in the EU Clinical Trials Register, EudraCT number 2013-004664-58.

FINDINGS: Between June 24, 2014, and Aug 23, 2016, 102 patients were screened, of whom 90 were randomly assigned to either azithromycin (n=49) or placebo (n=41). The study was ended without having included the planned number of participants due to recruitment difficulties. The mean number of respiratory exacerbations over 6 months was 0·75 (SD 1·12) in the azithromycin group compared with 1·62 (1·64) in the placebo group, and participants receiving azithromycin had significantly lower rate of exacerbations during the individual treatment periods (rate ratio 0·45 [95% CI 0·26-0·78]; p=0·004). Four serious adverse events were reported, occurring in one (2%) of 47 participants in the azithromycin group and in three (7%) of 41 participants in the placebo group. Loose stools or diarrhoea were more common in the azithromycin group than in the placebo group (11 [23%] vs two [5%]).

INTERPRETATION: This first multinational randomised controlled trial on pharmacotherapy in PCD showed that azithromycin maintenance therapy for 6 months was well tolerated and halved the rate of respiratory exacerbations. Azithromycin maintenance therapy is an option for patients with PCD with frequent exacerbations potentially leading to reduced need for additional antibiotic treatments and preventing irreversible lung damage.

FUNDING: European Commission Seventh Framework Programme and Children's Lung Foundation (Denmark).

Original languageEnglish
JournalThe Lancet Respiratory Medicine
Volume8
Issue number5
Pages (from-to)493-505
Number of pages13
ISSN2213-2600
DOIs
Publication statusPublished - May 2020

    Research areas

  • Adolescent, Adult, Airway Resistance, Anti-Bacterial Agents/administration & dosage, Audiometry, Pure-Tone, Azithromycin/administration & dosage, Blood Cell Count, C-Reactive Protein/analysis, Child, Ciliary Motility Disorders/drug therapy, Cytokines/blood, Diarrhea/chemically induced, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Quality of Life, Respiratory Function Tests, Sputum/microbiology, Young Adult

ID: 61984303